<DOC>
	<DOCNO>NCT01204710</DOCNO>
	<brief_summary>This study evaluate safety efficacy monoclonal antibody IMC-3G3 plus mitoxantrone plus prednisone compare mitoxantrone plus prednisone metastatic castration-refractory prostate cancer follow disease progression intolerance docetaxel-based chemotherapy .</brief_summary>
	<brief_title>A Study IMC-3G3 Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>histologicallyconfirmed adenocarcinoma prostate radiographic evidence metastatic prostate cancer ( stage M1 D2 ) prostate cancer unresponsive refractory medical surgical castration serum testosterone level &lt; 50 ng/mL disease progression intolerance docetaxelbased therapy PSA ≥ 10 ng/mL clinically significant toxic effect prior surgery , radiotherapy , chemotherapy hormonal therapy resolve ≤ Grade 1 , base National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) v 4.02 patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 adequate hematologic function adequate hepatic function adequate renal function urinary protein ≤ 1 dipstick routine analysis life expectancy 3 month fertile man partner woman childbearing potential must use adequate method contraception study sign Informed Consent document concurrent active malignancy adequately treat nonmelanomatous skin cancer noninvasive situ neoplasm The patient receive 1 prior cytotoxic chemotherapy regimen metastatic disease prior therapy mitoxantrone advanced prostate cancer The patient history symptomatic congestive heart failure pre study echocardiogram multigated acquisition scan leave ventricular ejection fraction ≥ 10 % low limit normal institutional range history prior treatment agent directly inhibit PDGF plateletderived growth factor receptor know allergy treatment component : IMC 3G3 , mitoxantrone , and/or prednisone radiotherapy within 21 day prior first dose IMC3G3 investigational therapy within 30 day randomization receive corticosteroid dose &gt; 5 mg prednisone orally ( PO ) 2 time per day ( BID ) equivalent receive prior strontium89 , rhenium186 , rhenium188 , samarium153 radionucleotide therapy either ongoing evidence bone marrow dysfunction poorly control bone pain ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness , active bleed pathological condition carry high risk bleeding , serious uncontrolled medical disorder know suspected brain leptomeningeal metastasis know human immunodeficiency virus infection acquire immunodeficiency syndromerelated illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>